IL-1 and Its Roots
==================

Historically in rheumatology, the seminal observation of the production of human interstitial collagenase (later called MMP-1) by human synovial cells in patients with rheumatoid arthritis (RA) led to the unraveling of the link between matrix degradation and the biological function of inflammatory molecules produced by immune cells. It was found that the main cellular source of both interstitial collagenase (matrix metalloproteases, MMPs) and prostaglandin E~2~ (PGE~2~) in synovial tissue were adherent stellate fibroblast-like cells (ASC), also called type B fibroblastic synovial lining cells ([@B24]). Presently, the fibroblast subpopulation in inflamed synovial tissue has proved to be far more complex ([@B15]).

The question was which are the driving forces for stimulating the synovial cells to produce MMP and PGE~2~. Seminal studies at the Arthritis Unit, Massachusetts General Hospital, Harvard Medical School) have shown that partial purification of the conditioned medium revealed a protein of approximately 15 kDa, and the factor responsible for this biological activity was called mononuclear cell factor (MCF) ([@B23],[@B25], [@B26]) (**Figure [1](#F1){ref-type="fig"}**). Interestingly, interactions between T cells and monocyte-macrophages were found to play an important role in the production of IL-1 by monocyte-macrophages, giving rise to the first descriptions of the pathways going from lymphocytes to monocyte-macrophages and synovial fibroblast cells ([@B20],[@B22]).

![**Seminal observation about the link between matrix degradation and the biological function of inflammatory molecules produced by immune cells (1976--1977).** (1) Cultures of synovial explants from patients with rheumatoid arthritis release large quantities of collagenase and prostaglandins (PGE2) into the media. Secretion of PGE2 declines more rapidly with respect to collagenase whose levels decline after different passages in culture; (2,3) The addition of monocyte-macrophages or their culture supernatants restored collagenase and PGE2 levels. The soluble factor responsible of this effect was later identified in mononuclear cell factor (MCF).](fphar-08-00293-g001){#F1}

At this early stage of the discovery, before the cloning, different investigators analyzed the soluble factors derived from leucocyte culture supernatants in their respective functional bioassays in order to identify the putative functional specificity. Purified 'MCF' proved to have similar properties to the lymphocyte-activating factor (LAF), a factor which had the same molecular weight of approximately 15 kDa and shared chromatographic as well as other biochemical properties ([@B56]). It was not until 1979 that the nomenclature and the terminology of interleukin-1 (IL-1), orchestrator of leukocyte communication, was coined at a meeting (Ermatingen, Switzerland) and it referred to products previously identified by several investigators using different bioassays, including lymphocyte activating factor (LAF), MCF, B lymphocyte activating factor (BAFF) and of course endogenous pyrogen (EP) that induced fever. At that time, cytokines were defined only by biochemistry ([@B1]). It was defined for the biochemistry properties by a m.w. between 12,000--18,000 with an isoelectric point of 4.5--5.5 in mouse and 6.5--7.5 in human, pH 2 insensitive, does not contain Ia and for the biologic properties as produced by macrophages, with H-2 unrestricted activity, unrestricted species activity, distinguishing bioactivity and does not possess the ability to promote and maintain *in vitro* long-term cultures of T cells in contrast to IL-2.

When human IL-1 was cloned using an antibody to EP and based on its EP bioactivity, the protein was expressed and the recombinant IL-1 found to have the same biological functions as MCF ([@B21]). However, it must be emphasized that in addition to IL-1, natural tumor necrosis factor-cachectin (TNFα) was also demonstrated early on to induce MMP and PGE2 production in synovial cells ([@B18]).

As far as LAF is concerned, despite the initial description of its role in the early activation of murine T cells from thymocytes, diseases characterized by an adaptive immune response to specific autoantigens are usually not part of the spectrum of IL-1β-driven disorders.

With regard to the field of rheumatology, other partially purified molecules like catabolin -- inducing cartilage degradation -- and osteoclast-activating factor (OAF) inducing calcium^45^ release from bone, to name but a few, were also found to have functions similar to those of IL-1 ([@B17]).

The discovery of the other aspects of the IL-1 and IL-1 receptor families, related to the seminal features of EP and to several other important functions, has been extensively reviewed ([@B29], [@B30]; [@B31]; [@B41]; [@B36]) as well as the biology of IL-1 alpha ([@B28]). The role of IL-1 in rheumatology and its specific interaction with MMPs have also been recently reviewed ([@B71]; [@B27]).

The Story Behind IL-1Ra
=======================

As early as 1984, before IL-1 was cloned, the existence of a potential natural inhibitor to IL-1 was suspected. In the bioassay for stimulating collagenase and prostaglandin production, no IL-1 biological activities were detected in the serum or urine of febrile patients ([@B4]). In the light of that finding, Dayer and colleagues (University of Geneva, Switzerland) reported in 1984 that, after biochemical purification, IL-1 was masked by a factor of approximately 17 kDa in the urine of febrile patients with monocytic leukemia and juvenile rheumatoid arthritis (JRA). This seminal observation was presented in 1984 at the Fourth International Lymphokine Workshop ([@B4]). The factor specifically blocked the biological activities of IL-1 ([@B16]; [@B5]).

The first description of the concept underlying the interleukin-1 receptor antagonist (IL-1Ra) was that this natural antagonist could block the binding of a cytokine from the same family to its receptor without affecting those of TNFα ([@B74],[@B75]). In the field of cytokine, it was the first observation of an inhibitor factor that blocks ligand binding of cytokine and its activities. The discovery of the competitive binding assay of the IL-1 inhibitor (apparent m.w. around 17 kd) to IL-1 at the IL-1 receptor level was crucial for researchers at Synergen (Boulder, CO, United States) who purified and cloned IL-1Ra in 1990. Before IL-1Ra was cloned, the first clinical description of natural IL-Ra was made by following the time course of this specific IL inhibitor in the serum and urine of children with systemic juvenile chronic arthritis, a typical inflammatory syndrome ([@B60]). [@B3] reported the presence of an inhibitor of IL-1 activity under *in vitro* conditions, but neither its molecular weight nor the concept of binding to the IL-1 receptor was identified.

IL-1 and Its Extended Family
============================

First described as a secreted product of monocytes and neutrophils ∼35 years ago, interleukin (IL)-1 refers to IL-1α and IL-1β. At present, the IL-1 family comprises a total of 11 members, consisting of the two activating cytokines IL-1α and IL-1β, the IL-1Ra, as well as IL-18, IL-33, four isoforms of IL-36 \[IL-36α, IL-36β, IL-36γ and IL-36 receptor antagonist (IL-36Ra)\], IL-37 and IL-1 family member 10 (also known as IL-38). IL-1 is processed and activated by a caspase-1-dependent mechanism as well as by caspase-1-independent processes that involve neutrophil proteases (see history in [@B36]).

Interleukin-1 receptor antagonist, IL-36Ra and IL-37 are predominantly anti-inflammatory cytokines. IL-36Ra shares homology with IL-1Ra but is unable to bind to the IL-1R1 ([@B59]). It has an important role in regulating skin inflammation and its deficiency (linked to mutations in IL-36RN) is associated to a rare form of pustular psoriasis also called deficiency of IL-36-receptor antagonist or DITRA ([@B53]). Skin lesions, along with multifocal osteomyelitis and periostitis are associated also to IL-1Ra deficiency, termed DIRA, an autosomal recessive autoinflammatory disease caused by mutations affecting IL1RN ([@B2]).

Inflammasome, the Macromolecular Complex
========================================

The discovery of the macromolecular complex inflammasome resulted from observations made by investigators working with rare diseases (autoinflammatory syndromes), experts in apoptosis, and biochemists analyzing how cells sense the presence of danger. The first to identify the mechanism was a French consortium of scientists in 1997, which was due to the mutation causing familial Mediterranean fever (FMF). The mutated gene encoding an unusual structure of unknown function -- named at that time marenostrin (from *mare nostrum*, referring to the Mediterranean Sea) -- a pyrin involved in periodic fevers ([@B40]). The protease which processes interleukin-1β \[IL-1β-converting enzyme (ICE) = caspase-1\] was identified in 1989 ([@B7]) and cloned in 1992 ([@B12]; [@B86]). The identification of CARDIAK, a death domain associated with caspase-1, was identified in 1998 ([@B85]). The mutation in the gene (currently called NLRP3-inflammasome) in recurrent and chronic inflammation was initially detected in a group of rare autoinflammatory conditions, termed cryopyrin-associated periodic syndromes (CAPS) ([@B44]); this protein also belongs to the pyrin family. The link between pyrin, cryopyrin, NLRP3, death domain (CARD) and caspase-1 was established and this macromolecule complex was termed "inflammasome" ([@B54]; [@B81]) (**Figure [2](#F2){ref-type="fig"}**).

![**From fever of unknown origin to the inflammasome puzzle**.](fphar-08-00293-g002){#F2}

IL-1 Receptors
==============

The search for IL-1 receptors began in 1985 when a high-affinity plasma membrane receptor for human interleukin was identified ([@B33]); between 1985 and 1988, numerous investigators were working in this field of research ([@B6]; [@B49]; [@B50]).

The gene sequence for IL-1β and IL-1Ra receptors was described by [@B78]. [@B83] was well established that the type I and not type II receptor led to signal transduction.

[@B35] demonstrated the existence of an IL-1β binding protein, followed by the findings of Francesco Colotta and Alberto Mantovani in 1993 that the shed molecule of type II receptor was a decoy receptor and probably similar to the IL-1β-binding protein described by Eastgate and Duff.

In a recent book entitled "Body Messages: the Quest for the Proteins of Cellular Communication. Evolution of Message Discovery: The IL Family," [@B36] elegantly describes the different facets, controversies and surprises characterizing the discovery of the IL-1, IL-1Ra and interleukin receptors families.

Inflammasome, IL-1 and IL-Ra in Crystal-Induced Arthropathies
=============================================================

The first observation that IL-1 could contribute to the pathogenesis of crystal-induced arthritis [@B34] demonstrated that monosodium urate (MSU) crystals were able to stimulate mononuclear phagocytes *in vitro* to produce EP. The authors failed to extend these results to other pathogenic crystals such as hydroxyapatite and calcium pyrophosphate (CPP), hypothesizing that the joint had to be, in some way, "conditioned" to propagate an inflammatory stimulus and that the source of IL-1 could lie outside the joint ([@B52]). Subsequently, it became clear that purified crystals alone could not induce IL-1but that an additional stimulus was needed *in vitro* to generate IL-1 ([@B42]). Further *ex vivo* models identified free fatty acids ([@B46]) and synovial fluid (SF) proteins ([@B69]) as important triggers of IL-1 release.

An imbalance between the production of IL-1 and IL-1Ra induced by crystals in activated cells was pointed out in 1994 when it became clear that MSU and CPP crystals did not affect IL-1Ra production in neutrophils ([@B65]).

[@B55] demonstrated for the first time the involvement of the inflammasome NLRP3 in caspase-1 activation and IL-1 release induced by crystals. IL-1R was also found to play a critical role in amplifying the inflammatory response through a MyD88-dependent mechanism ([@B13]). These observations, along with the discovery that uric acid was capable to stimulate the innate immune system ([@B77]), led to the addition of gout to the spectrum of autoinflammatory diseases ([@B61]).

The key role that IL-1β plays in gout and pseudo-gout was further confirmed by the effectiveness of blocking agents to IL-1 in that it reduced acute attacks, initially observed after the administration of IL-1Ra anakinra, and then to the anti-IL-1β monoclonal antibody canakinumab ([@B80]; [@B72]; [@B62]). Accordingly, the recent EULAR recommendations for the management of gout advocate considering the administration of IL-1 blockers in those patients with frequent flares and contraindications to colchicine, NSAIDs and corticosteroids ([@B64]). In contrast, Rilonacept, a soluble receptor fusion protein binding both IL-1α and IL-1β, provided no benefit over indomethacin in an RCT ([@B84]). Other promising molecules, such as the recombinant human alpha-1-anti-trypsin (AAT)-IgG1 Fc fusion protein, have been shown to mainly target IL-1 in gout ([@B45]).

Effect of IL-1 on Cartilage and Bone in OA
==========================================

The presence of a low molecular weight peptide released from synovial tissue and able to affect cartilage homeostasis was demonstrated at the end of the 1970s ([@B32]). This messenger called "catabolin" was able to stimulate chondrocytes to degrade both cartilage proteoglycans and collagen ([@B66]), and soon its similarity to IL-1 was established ([@B67]).

[@B43] demonstrated for the first time that IL-1-like factor altered the breakdown of bone by modulating both bone resorption in RA and bone formation in OA. As far as bone resorption is concerned, IL-1Ra was later shown to block the resorptive effect induced by IL-1 *in vitro* ([@B73]).

Despite the fact that the altered expression of proinflammatory cytokines and chemokines in OA cartilage and synovium is well documented ([@B47]; [@B63]), the role of IL-1β has not been fully clarified. Very low levels of IL-1β have been determined in the synovial membrane and SF of patients with early and end-stage OA ([@B70]) although levels were more elevated in the SF cells of OA than in those of controls ([@B68]). However, IL-1β levels are significantly lower in OA than in RA ([@B37]). *In vitro* studies have revealed that IL-1β plays a critical role in driving the production of proteolytic enzymes such as MMPs and ADAMTS-4 in OA ([@B9]). But results obtained from different OA animal models showed discrepancies when anti-IL-1β therapy ([@B38]; [@B88]) or mice deficient in IL-1 ([@B14]) were utilized, thus emphasizing that other, IL-1-independent, pathways may be involved in OA pathology ([@B8]).

As far as the association between the IL-1 gene polymorphisms and OA is concerned, the haplotypes IL1A-IL1B-IL1RN and IL1B-IL1RN have, respectively, been shown to confer a higher and a decreased risk of OA ([@B79]). A study investigating the contribution of gene polymorphisms to dysregulated cytokine expression in OA cartilage revealed significant associations between the TNFα (high) chondrocyte phenotype and IL-1Ra allele 2, and between the TNFα (low) phenotype and IL-1β allele 2 ([@B57]).

An association between severe hand OA and single nucleotide polymorphisms in the IL-1R1 gene has been observed in family based and case-control analyses ([@B58]). Several studies assessing the polymorphism in OA are ongoing, and some have been reviewed in a meta-analysis ([@B48]).

Toward Clinical Implications
============================

Although IL-1 itself has been used as a therapeutic agent in oncology patients, alone it has little antitumor activity in melanoma, renal cell carcinoma, ovarian carcinoma or other diseases.

Considering that IL-1 seems to protect and restore the bone marrow from lesions induced by radiation or chemotherapy, it has been proposed to use it for treatment, but its modest hematopoietic effects probably do not counterbalance the toxicity necessary to achieve said effects ([@B87]). IL-1α and IL-1β have also been proposed as vaccine adjuvants ([@B82]).

The initial attempts to block IL-1 in infectious diseases have been unsuccessful and were accompanied by an increase in infections and side effects ([@B39]). Trials monitoring effects of IL-1Ra in patients with RA, which were begun in 1991, have produced interesting results although long-term results have not proved impressive and have demonstrated that this therapy is less effective than anti-TNF therapies. The initial trial targeting IL-1 in RA has been reviewed in detail ([@B19]).

At present, therapeutic blockade of IL-1 is crucial in many hereditary autoinflammatory diseases, as well as in patients with Still's disease, crystal-induced arthropathies, certain skin diseases including neutrophil-triggered skin diseases, Behçet's disease and deficiency of IL-1Ra, and other rare fever syndromes. Its effects have been marginal in RA patients and are still under debate in OA, type 2 diabetes mellitus, cardiovascular diseases and cancer ([@B51]; [@B10]; [@B11]; [@B76]).

Relevant developments are still be expected in future with regard to the IL-1 family and the macromolecular complex which is inflammasome. The complexity of the various forms of the IL-1 receptor family, not discussed here in the history, is far from being fully understood and may lead to new avenues for pharmacological interventions.
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